Author

Thomas Tilton

University of Southern CaliforniaORCID 0009-0002-2535-7973Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:scRNA-seq· 2 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

De‐Chen LiniD· 2 shared Young Min ParkiD· 2 shared Benjamin ZimaniD· 1 shared Chehyun NamiD· 1 shared Chi ZhangiD· 1 shared Daniel ArnaudoviD· 1 shared Haiqi ZhuiD· 1 shared Joseph A. VargasiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

De‐Chen LinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MCT4-Associated Lactate Export Defines Myeloid Metabolic Reprogramming during Head and Neck Cancer Progression

Thomas Tilton, Young Min Park, Haiqi Zhu, Chi Zhang, De‐Chen Lin

The paper identifies increased MCT4-associated lactate export in myeloid cells during HNSCC progression using single-cell RNA-sequencing and metabolic flux analysis.

bioRxiv · Oct 16, 2026 · PreprintCancer Biology

ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune Evasion

Benjamin Ziman, Talia A. Wenger, Chehyun Nam, Qian Yang, Daniel Arnaudov, Thomas Tilton, Megha Sheth, Zhixuan Jing, Yuhao Pan, Joseph A. Vargas, Yong Teng, Uttam K. Sinha, Young Min Park, De‐Chen Lin

This study identifies ETS1 as a master regulator of a hybrid EMT program in UASCC that drives metastasis and immune evasion, and shows HSP90 inhibitors can target ETS1-driven tumors.

Cancer Research · May 19, 2026Peer-reviewedCancer Biology